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• Few effective standard options available for patients with refractory disease
• Identiﬁcation of genomic alterations can inform treatment decisions.
• Point-of-care management using this approach is feasible.
• A molecular tumor board (MTB) is an important component of point-of-care management.
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Accepted 21 February 2016Objective. To determine the feasibility and clinical utility of using comprehensive genomic proﬁling (CGP) in
the course of clinical care to identify clinically relevant tumor genomic alterations for patients with either rare or
refractory gynecologic cancers to facilitate point-of-care management. Use of an expert, multidisciplinary, insti-
tutional molecular tumor board (MTB) assessment is discussed regarding input on putative targeted options for
individualized therapy.
Methods. A prospective clinical trial is ongoing. We report on the initial 69 patients with gynecologic cancers
that were either rare or refractory to standard therapy. CGP was performed by Foundation Medicine, Inc. Geno-
mic alterations were reviewed by members of an MTB. Consensus recommendations on genomically targeted,
FDA-approved, on- and off-label therapies and clinical trials were sent to the treating physician, and decisions
and outcomes were assessed.
Results. Study outcomeswere available for 64patients. Themeannumber of genes alteredper tumorwas 4.97
(median= 4; range, 1–26), and the average turnaround time from testing laboratory report to generation of for-
mal recommendationswas approximately threeweeks. Evaluation of genomic and clinical data by theMTB led to
generation of targeted treatment options in all 64 patients, and the percentage of patients for whom one ormore
of these recommendations were implemented by the treating physician was 39%. Sixty-four percent of the pa-
tients receiving targeted therapy based on a CGP result experienced radiologic response or showed evidence of
clinical beneﬁt or stable disease.
Conclusion. These data suggest that an institutionalMTB is a feasible venue for reviewing tumor genomic pro-
ﬁling results and generating clinical recommendations. These data also support the need for further studies and
guidelines on clinical decision making with greater availability of broad genomically based diagnostics.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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uez-Rodriguez),
. This is an open access article under1. Introduction
In 2015, the estimated number of cases of gynecologic cancer, in-
cluding ovarian, endometrial, cervical, vaginal, and vulvar cancers,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3L. Rodriguez-Rodriguez et al. / Gynecologic Oncology 141 (2016) 2–9occurring in the United States was approximately 98,000 with over
30,000 deaths [1]. Several factors contribute to this high mortality
rate: the majority of ovarian cancers are diagnosed at an advanced
stage and most advanced endometrial cancers recur following initial
standard of care therapy. Furthermore, standard therapy options are
very limited in patients with ovarian or endometrial cancer that is re-
current or refractory to initial therapy [2,3]. Thus, novel treatment op-
tions, but especially targeted therapies for the treatment of advanced
gynecologic cancers, represent a major unmet need.
It is becoming increasingly clear that both ovarian and uterine can-
cers are highly heterogeneous diseaseswith respect to prognosis, sensi-
tivity to standard cytotoxic therapy, tumor histology, and the
underlying molecular characteristics of the tumor. Clinicopathologic
and molecular studies of epithelial ovarian cancers (EOCs) have pro-
vided the basis for simplifying the classiﬁcation of these tumors into
two categories that provide insight into the mode of tumorigenesis:
type I (including low-grade serous, endometrioid, mucinous and clear
cell cancers) and type II (including high-grade serous tumors) [4,5].
On a genomic level, mutations in potential oncogenic driver genes
such as KRAS are much more commonly observed in type I compared
with type II EOCs [4]. In addition, genomic alterations in other regulators
of the mitogen-activated protein kinase (MAPK) pathway (e.g., BRAF),
receptor tyrosine kinases (e.g., ERBB2), and loss-of-function mutations
in PTEN also occur at a higher frequency in type I tumors [5–7]. Regard-
ing type II EOCs, high-grade serous ovarian cancer is characterized by a
nearly ubiquitous presence ofmutations in TP53, a relatively high rate of
defects in BRCA1/2, and a higher burden of genomic alterations, which
are rarely seen in type I tumors [5,8–21]. Importantly, both DNA- and
RNA-based next-generation sequencing (NGS) technologies are provid-
ing the basis for a rapid expansion of our understanding of the spectrum
of molecular alterations occurring within ovarian cancers and their po-
tential impact on malignant behavior. For example, studies involving
the extensive characterization of the transcriptome of high-grade se-
rous ovarian cancer, as well as the exomes of both newly diagnosed
and chemoresistant, recurrent high-grade serous ovarian cancer have
been reported [9,22,23], and some of these data are available online
through The Cancer Genome Atlas (TCGA) project.
Uterine cancer includes endometrial carcinoma and the relatively
rare uterine sarcomas, including leiomyosarcoma and carcinosarcoma
[24,25]. The histological subtypes of endometrial adenocarcinoma in-
clude endometrioid, clear cell, serous, mucinous, and mixed-cell carci-
noma histologies [26]. Endometrial cancers have been classically
categorized into two prognostic groups on the basis of overall tumor
characteristics and patient metabolic and endocrine-related risk factors
[7,27]. More recent detailed genomic proﬁling of endometrioid and se-
rous endometrial carcinomas by the TCGA and other groups have led
to themolecular reclassiﬁcation of endometrial carcinoma into four dis-
cretemolecular subgroups with different genomic landscapes, resulting
in a molecular classiﬁcation scheme that is distinct from the overlaying
histological classiﬁcation [28,29].
Despite the usefulness of these classiﬁcation schemes in characteriz-
ing ovarian and endometrial cancers, the current standards of care for
the treatment of these diseases are primarily based on morphological/
histological subtype, tumor stage, and tumor grade, with few effective
standard options available for patients with refractory or recurrent dis-
ease [2,3]. However, recent technological advancements in tumor geno-
mic sequencing have made it possible to use the new molecular
taxonomy of cancer available through large research databases, such
as the TCGA. In this precision medicine approach, identiﬁed and poten-
tially “actionable” genomic alterations can inform treatment decisions
for individual patients in the setting of routine clinical care, particularly
in cases where conventional cancer assessments and treatments are
suboptimal. Nevertheless, the feasibility and clinical utility of such an
approach is still unclear.
Here, we report results for the initial cohort of patients with gyneco-
logic cancers enrolled in an ongoing comprehensive, prospectivegenomic proﬁling protocol at the Rutgers Cancer Institute of New Jersey
(CINJ). Themain goal of the studywas to investigate the rate of putative
actionablemolecular alterations of this set of tumors. Of particular inter-
estwas to determine the feasibility and the impact of point-of-care test-
ing of tumor somatic molecular alterations on decisions related to
subsequent therapy in this cohort of “real-time” patientswith rare or re-
fractory gynecologic cancers.
2. Methods
2.1. Study participants
An initial subgroup of 67 patients with gynecologic cancers were en-
rolled onto an institutional review-board approved, prospective study
trial at the Rutgers CINJ from 2013 through 2015 for the genomic proﬁl-
ing of patients with rare or refractory cancers. Two additional patients
were presented retrospectively to the tumor board off protocol and
are also included here. Detailed results for theﬁrst 100 patients enrolled
in the parent study observing various tumor types have been previously
reported [30]. Our analysis of patients with gynecologic cancers
consisted predominantly of those with ovarian or uterine cancers that
were rare and/or refractory to prior therapy. A small number of patients
with advanced vaginal or cervical cancers were also included. Inclusion
criteria included: Age ≥ 1 year (allowing for inclusion of pediatric pa-
tients), prior conﬁrmed diagnosis of rare cancer or cancer with a poor
prognosis with standard therapy, and available tumor tissue sample.
2.2. Genomic proﬁling through comprehensive genomic proﬁling
Tumor specimens were evaluated by histologic examination of he-
matoxylin and eosin stained sections. Formalin-ﬁxed, parafﬁn-
embedded tumor specimens from patients in this trial underwent hy-
brid capture-based comprehensive genomic proﬁling (CGP) in a Clinical
Laboratory Improvement Amendments (CLIA)-approved, New York
State accredited commercial laboratory (Foundation Medicine, Inc,
Cambridge,MA) [31]. Sequencing initially included the entire coding re-
gions of 236 cancer-related genes as well as 47 introns of 19 genes in-
volved in fusions. Later in the study, the panel was expanded to
include 315 cancer-related genes aswell as introns of 28 genes involved
in fusions. The speciﬁc assay version usedwasdetermined by the date of
patient enrollment in the study. All classes of genomic alterations were
assessed: DNA single-base mutations (i.e., single-nucleotide variants,
including missense, or nonsense mutations leading to the insertion of
a different amino acid or a stop codon, respectively), small DNA inser-
tions or deletions, copy number alterations, and gene rearrangements.
2.3. Molecular Tumor Board (MTB) assessment
The MTB team consisted of experts from various disciplines includ-
ing medical oncologists, surgical oncologists, pathologists, clinical
trialists, systems biologists, genetic counselors, and biomedical research
scientists. Team discussions of CGP results of individual patients within
the context of patient-, disease-, and treatment-related factors focused
on reﬁning diagnosis, gaining additional insight into the natural history
of the disease, and tailoring therapy for each patient. Consensus recom-
mendations regarding clinical trials and on- and off-label FDA-approved
therapeutic approaches were sent in a formal letter to the treating phy-
sician. Clinical recommendations included targeted therapies based on
each patient's tumor genomic proﬁle, applicable clinical trials, as well
as guidance related to the need for serial biopsy and germline testing.
Targeted therapies included FDA-approved, on- or off-label targeted
therapies, cytotoxic agents, or radiation therapy for patients with tu-
mors characterized by DNA repair pathway defects. The proportion of
study participants receiving therapy consistent with the consensus
recommendations and patient outcomes was determined through
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September 4, 2015.
3. Results
3.1. Patient and disease characteristics
Baseline patient and disease characteristics are presented in Table 1.
Sixty-nine patients with rare or refractory gynecologic cancer evaluated
at the CINJ had either enrolled in the clinical trial or been presented ret-
rospectively to the tumor board off protocol (n= 2) since its initiation
in 2013. The median patient age was 61 years (range, 22–80), and pa-
tients were classiﬁed as White (77%), Black/African American (13%),
Asian (7%), or Hispanic (3%). Tumor types included ovarian cancer
(n= 41), uterine cancer (n= 25), vaginal cancer (n= 2), and cervical
cancer (n=1). A wide range of morphologic/histologic disease charac-
teristicswas identiﬁedwithin ovarian and uterine cancers. Ovarian can-
cers included refractory EOCs, rare tumors of stromal or germcell origin,
and carcinosarcomas. Uterine cancer tumors included endometrioid ad-
enocarcinomas, papillary serous and clear cell tumors, and uterine
sarcomas.
One patient was excluded from the study prior to tumor genomic
proﬁling because the tumor specimen was deemed inadequate. of the
68 patients whose tumors were genomically proﬁled, two patients
were found to have no detectable alterations, one patient was not pre-
sented at theMTB, and one case was originally thought to be an ovarian
primary butwas ultimately determined to be a pancreatic primary. Spe-
ciﬁcally, this latter patient was initially diagnosed with mucinous
ovarian cancer, but subsequent pathologic and genomic analyses of
the tumor specimen suggested primary pancreatic cancer that had
metastasized to the ovary. While the baseline data reﬂect the entireTable 1
Baseline patient and disease characteristics.
Age, years
Median 61
Range (22–80)
Race/Ethnicities, n (%)
White 53 (77%)
Black/African American 9 (13%)
Asian 5 (7%)
Hispanic 2 (3%)
Ovarian Cancer All histologies
No. patients, n 41
Mean age 59
Stage unavailable 9
Stage I cases 1
Stage II cases 4
Stage III cases 22
Stage IV cases 4
Unstaged cases 1
Karnofsky Performance Score, mean 84
Uterine Cancer All histologies
No. patients, n 25
Mean age 66
Stage unavailable 7
Stage I cases 9
Stage II cases 0
Stage III cases 3
Stage IV cases 6
Karnofsky Performance Score, mean 88
Other Cancers All histologies
No. patients, n 3
Mean age 56
Stage IV cases 3
Karnofsky Performance Score, mean 88
Baseline characteristics of the initial 69 patients with gynecologic cancers enrolled in this
study. Disease stage was determined at patient diagnosis; Karnofsky performance scores
and percentages of patients with recurrent or progressive disease were determined at
study enrollment; ovarian and uterine cancer histologies are identiﬁed in Fig. 2; ovarian
cancer includes patients with fallopian tube and primary peritoneal cancer.panel of 69 patients, the analyses of genomic proﬁles and clinical
outcomes include only the remaining 64 patients, who were found to
have at least one detectable gene alteration (Fig. 1).
The majority of patients with ovarian cancer were diagnosed with
Stage III or IV disease (n=24, 59%). At the time of study entry, most pa-
tients with ovarian cancer had good performance status based on their
Karnofsky performance scores. The mean patient age was 59 years. Of
the 25 patients with uterine cancer, 14 had endometrial adenocarci-
noma (i.e., papillary serous, endometrioid, clear cell histologies) and
11 had uterine sarcomas (i.e., leiomyosarcoma, carcinosarcoma, and
adenosarcoma). Nine (36%) patients with uterine cancer had an initial
diagnosis of early-stage (Stage I) disease. Patients with either vaginal
cancer or cervical cancer (n= 3) had metastatic disease and good per-
formance status at study enrollment.
For the 64 patients for whom MTB-based therapies were recom-
mended, 81% of patients (n = 52) had recurrent/progressive disease
at the time of CGP. The remaining patients (n= 12) had primary dis-
ease; eight of those patients were diagnosed with sarcomas. Of the pa-
tients who received prior therapy (n= 52), the mean number of prior
regimens was 3.1 (median = 3; range, 1–7).
3.2. Genomic analysis of tumor specimens
All patients included in this analysis (n = 64 patients) had at least
one gene alteration (mean=4.97;median= 4; range 1–26). The dura-
tion between acquisition of the tumor specimen and date of consent for
study enrollment was b90 days for approximately half of the overall
study population forwhomMTB recommendationsweremade, indicat-
ing that the tumor specimens sequencedwere representative of the cur-
rent disease state in a considerable proportion of patients included in
this analysis.
A detailed list of all somatic genomic alterations identiﬁed in tumor
specimens of each of the 64 patients receiving MTB-based therapeutic
recommendations is provided in Supplementary Table I. The distribu-
tion of ovarian cancer and uterine cancer subtypes and the most com-
monly altered genes (ie, the genes with alterations that were
observed in at least four patients plus CDKN2A and CDKN2B in speci-
mens of ovarian cancers and the genes with alterations that were ob-
served in at least ﬁve patients in specimens of uterine cancer) as a
function of these subsets are depicted in Fig. 2. Consistent with ﬁndings
from the TCGA, the gene most commonly altered among both ovarian
and uterine cancers was TP53 (n = 26 and 19, respectively) [9,28]. In
addition to TP53, ovarian cancers, including both serous and non-
serous subtypes, demonstrated alterations most commonly in MYC,
KRAS, CCNE1, BRCA1/2, NF1, PIK3CA, and CDKN2A/B. Of these genes, al-
terations in one or more specimens of ovarian carcinosarcomas were
found in TP53,MYC, CCNE1, BRCA2, CDKN2A/B,NF1, and PIK3CA (Fig. 2A).
Among uterine cancers, the most commonly altered genes were
TP53, PIK3CA, ARID1A, PTEN, LRP1B, FBXW7, and RB1. Of these genes, al-
terations in one or more specimens of carcinosarcomas were found in
TP53, PIK3CA, PTEN, LRP1B, FBXW7, and RB1. In addition, some tumor
specimens of the endometrioid and leiomyosarcoma subtypes exhibited
alterations in ARID1A, LRP1B, and RB1 (Fig. 2B).
Of note, both ovarian and uterine cancers demonstrate genomic
gene alterations in components of well-characterized, molecular pro-
cesses/pathways, such as the PI3K/mammalian target of rapamycin
(mTOR) pathway, previously described to be dysregulated in cancers
[32–35]. Overall, 93% of all patients included in this analysis had one
or more clinically relevant genomic alterations identiﬁed in their
tumor specimens (64 of 69 patients).
3.3. Parameters associated with molecular tumor board effectiveness
3.3.1. Feasibility
After testing resultswere received, theMTBmembers performed in-
depth research and analyses of the results. With this in mind, it was
Fig. 1. Flow diagram representing patient selection.
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tions was reasonable in the context of point-of-care patient treatment.
The average duration of time from the receipt of genomic testing results
to the generation of a formal summary of treatment options made by
the MTB for the treating physician was approximately 3 weeks (data
not shown). As previously mentioned, MTB-based therapeutic recom-
mendations were made for 93% of patients (64 of 69 patients), based
on MTB analysis of their CGP results. Data on whether MTB-based ther-
apeutic recommendationswere offered to the patient and implemented
by the treating physician are shown in Fig. 1. Twenty-ﬁve patients (39%)
had anMTB-recommended therapy implemented by their treating phy-
sicians. Thirteen patients had MTB-recommended treatments offered
by their treating physicians, but treatment was not implemented.
Twenty patients were not offered MTB-based therapy by their treating
physicians. No information is available or known for six patients. The
proportion of patients receiving MTB-based therapy at start of this
trial and then in subsequent years is shown in Fig. 1. These results
show a substantial increase in the proportion of patients receiving an
MTB-based therapy for the years 2014 and 2015 compared with 2013
(5-fold for 2014 and nearly 7-fold for 2015). Reasons for patients not re-
ceiving or physicians not offeringMTB-based therapies included the fol-
lowing: patient had no evidence of disease and therewas no evidence of
advantage of adjuvant targeted therapy, patient had deteriorating per-
formance status or died shortly before or after case was presented at
the MTB meeting, patient was lost to follow-up. In other instances, the
patient chose another facility or refused MTB-based therapeutic option
or any further treatment. In other instances, the patient declined the
MTB-recommended clinical trial, the drug could not be obtained due
to insurance denial, the recommended drugwas contraindicated, no ap-
propriate clinical trial was available, or the treating physician opted for a
different treatment.3.3.2. Clinical utility
As previously mentioned, 25 patients were offered MTB-based rec-
ommendations and at least one of the recommended options was im-
plemented by their treating physicians (Fig. 1). Examples of
implemented MTB-based therapies included the use of anmTOR inhib-
itorwith orwithout an aromatase inhibitor [36], or aMEK inhibitor [37],
in patients with endometrial carcinoma characterized by a PIK3CA or
PI3K pathway mutation or a KRAS mutation, respectively. In addition,
platinum-based chemotherapy or radiation therapy was recommended
in patients with genomic evidence of defective DNA damage repair,
such as mutations in BRCA2 or ATM, respectively [38,39]. Clinical trials
were the preferred MTB-based therapeutic recommendation, when
available. MTB-based therapeutic options included at least one clinical
trial for 40 of the 64 patients (63%) included in this analysis. However,
of the 25 patients receiving an MTB-based therapy, only 12% (n = 3)
were treated in the setting of a clinical trial.
Available details for each patient with respect to speciﬁc clinical
endpoints (e.g., progression-free survival (PFS) before and after pre-
sentation at MTB are summarized in Table 2. The rate of response
(complete response (CR), partial response (PR)), stable disease
(SD), or progressive disease (PD) by RECIST 1.1 criteria of radiologic
ﬁndings or a clinical beneﬁt (CB) deﬁned as improvement of symp-
toms or evidence of biochemical response (eg, a reduction in CA-
125 levels) without available response criteria, as per RECIST 1.1,
was determined [40]. We deﬁned PFS as the ﬁrst day of MTB-
based therapy to the ﬁrst day of radiologically proven disease pro-
gression or clinical disease progression. Of the 23 patients who re-
ceived MTB-based therapy and for whom PFS data was available, all
experienced PFS durations of 30 days or longer (Fig. 3, Table 2).
Sixty-four percent of patients (16 of 25 patients) who receivedMTB-
based therapy recommendations had a CR, PR, SD, or CB. In addition, the
Fig. 2.Tumor histological subtypes andgenesmost commonly altered, as evaluated by theMTB. A.Distribution of ovarian tumorhistological subtypes (pie chart) and the count of the genes
with alterations that were observed in at least four patients plus CDKN2A and CDKN2B in tumor specimens of ovarian cancer (n = 36) (bar graph). B. Distribution of uterine cancer
histological subtypes (pie chart) and the count of the genes with alterations that were observed in at least ﬁve patients in tumor specimens of uterine cancer (n= 25) (bar graph).
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tion of PFS on prior therapy for 26% of patients (6 of 23 patients) within
that subgroup. Seven of 23 patients (30%) exhibiting a radiologic re-
sponse, SD, or CB following the administration of MTB-based therapies
have ongoing responses; therefore, PFS is still to be determined for
these patients. The duration of PFS was longer on the MTB-based ther-
apy compared with the prior therapy for three patients in the subgroup
with ongoing PFS. Seventeen patients had longer durations of PFS on
prior therapy compared with MTB-based therapy (Fig. 3, Table 2). Of
note, 61% of patients, whose clinical courses are described in Fig. 3 and
Table 2, had become platinum (11 of 23 patients) or taxane (3 of 23 pa-
tients) refractory prior to the MTB assessment.
4. Discussion
The integration of molecular testing and molecularly targeted ther-
apy into the diagnosis and treatment of certain cancers, such as non-small cell lung cancer, melanoma, and chronic myeloid leukemia, has
become part of the standard of care for patients diagnosed with these
diseases. However, despite the increasing body of knowledge related
to the molecular proﬁles of ovarian and uterine cancers made possible
through recent advances in NGS technologies [9,28], molecularly
targeted therapy for the treatment of these diseases, with the
exception of BRCA1/2-directed therapy in ovarian cancer, remains in-
vestigational. Furthermore, the therapeutic armamentaria are even
more limited for patients with rare gynecologic cancers.
A number of studies have provided evidence suggesting improved
clinical beneﬁt for patients with advanced cancer receiving genomically
informed therapy over those who are not [41–44], and several ongoing
randomized clinical trials of patients with advanced cancer, including
theMATCH, I-SPY2, and PROSPECT trials, are incorporating genomic in-
formation identiﬁed through NGS methods [45–47]. However, one of
the main rationales for undertaking this analysis of a subgroup of pa-
tients enrolled in a prospective clinical study of cancer patients being
Table 2
Summary of clinicopathologic features and patient outcomes for patients receiving MTB-
based therapy.
Patient
number
Histology PFS (days) for last
treatment prior to
TB
recommendations
PFS (days) on
MTB-based
therapeutic
option
Tumor
response
(CB, CR, PR,
SD, PD)
Ovarian cancer
1 Stromal cell 468 202 N/A
14 Mucinous cancer NA 91 PR
15 Papillary serous 200 200 PR
17 Papillary serous 622 460 CB
19 Papillary serous 364 459→ SD
20 Papillary serous 199 36 PD
21 Papillary serous 232 43 UNK
22 Papillary serous 384 180 N/A
23 Mucinous N/A N/A CR
24 Unknown histology 284 51→ PR
27 Carcinosarcoma 68 128 SD
33 Carcinosarcoma N/A N/A UNK
35 Clear cell 347 140→ CB
36 Transitional cell 320 229 PR
38 Papillary serous 20 43→ UNK
39 Papillary serous 120 62 PR
Uterine cancer
44 Endometrioid 148 78 PR
49 Endometrioid 201 81→ PR
50 Clear cell 522 138 PR
51 Endometrioid 325 41 PD
54 Leiomyosarcoma 761 234→ N/A
60 Endometrioid 92 96→ SD
61 Endometrioid 210 182→ PR
63 Carcinosarcoma 161 56 PD
64 Endometrioid 265 70→ SD
This table represents the patients who received MTB-based therapeutic options; Ovarian
cancer includes patients with fallopian tube and primary peritoneal cancers.
The patient numbers are for reference within this article only and do not correspond to
participant identiﬁers from related articles.
• Abbreviations: CB = clinical beneﬁt, CR = complete response, PR = partial response,
SD = stable disease, PD = progressive disease, PFS = progression-free survival, MTB
=molecular tumor board, UNK = unknown
• Clinical beneﬁt = improvement of symptoms or evidence of biochemical response
(e.g., a reduction in CA-125 levels) without available response criteria, as per RECIST 1.1
• CR, PR, SD, and PD were assigned based on RECIST 1.1 criteria.
• Treatments may have been provided in the setting of a clinical trial, even if not speciﬁ-
cally noted here.
• Data was last monitored for this paper on September 4, 2015. The designation of “ongo-
ing” (represented by arrows) is based on the patient's last physician visit or the patient's
status as of September 4, 2015.
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utility of using a genomically informed treatment decision-making ap-
proach in “real time” in a population of patients with gynecologic can-
cers. This is a proof-of-concept study and, as such, observational in
nature. A central feature of this study is the interpretation of molecular
information for each patient by a team of physicians and scientists with
broad expertise in the care of patients with cancer, the interpretation of
tumor molecular proﬁles, and the cellular processes underlying the de-
velopment and growth of the diseasewithin the context of clinically rel-
evant medical and radiographic evidence [30]. The results of this
analysis show that the turnaround time from receipt of CGP results
and generation of a formal summary of treatment options made by
the MTB is feasible with respect to inﬂuencing treatment decision-
making by the treating physician at the point of care, as it relates to
the immediate or next therapy. In addition, one or more potentially ac-
tionable or tumor-driving molecular alterations were identiﬁed in the
tumor specimens of 93% of patients included in the analysis, and the
numbers of patients receiving MTB-based therapy between 2013 and
2015 show a clear trend toward an increased clinical impact for this ap-
proach over time. MTB-based therapeutic recommendations included
relevant clinical trials (preferred); FDA-approved, on- or off-labeldrugs; germline testing; and rebiopsy to assess tumor evolution and re-
sistancemarkers. It is interesting to note in the progression of this study
that MTB recommendations were often not implemented in the ﬁrst
year of the trial, whereas, by the second and third years, an increase in
implementation occurred (Fig. 1). It is possible that a delay in physician
uptake or patient apprehension over the potential beneﬁt of these rec-
ommendations over standard of care earlier on in the study played a
role in the lack of implementation of MTB recommendations. Alterna-
tively, as the knowledge of the most common alterations observed in
our population became known,more clinical trials targeting those alter-
ations were opened at the CINJ, improving patient access. Furthermore,
over the period of this study, more targeted agents have been FDA-
approved and have become available for off-label use.
Perhaps most informative is the comparison of duration of PFS on
therapy initiated prior to the MTB meeting with PFS duration on
subsequent MTB-based therapy for each patient. Previous reports
of studies of phase I trials of patients with gynecologic cancers re-
ceiving targeted therapies have shown that PFS is either shorter or,
in some cases, comparable to the PFS duration achieved on prior
conventional therapies [48,49]. However, in the present study 26%
of patients receiving MTB-based therapy experienced PFS durations
similar to or longer than those experienced on prior therapy; some
of these were ongoing. This could be an indication of targeted therapy
effectiveness.
This analysis is limited by several factors. These include the observa-
tional nature of the study, the limited follow-up, and the relatively small
numbers of enrolled patients. Otherwise, the study is novel in its pro-
spective nature and its ability to detect trends in point-of-care applica-
tions. Approaches to improve the feasibility and clinical utility of
genomically driven, MTB-based therapeutic recommendations include
decreasing the time between the receipt of the tumor genomic testing
results and their analysis by the MTB and subsequent communication
of MTB recommendations to the treating physician. Nevertheless, our
results show that CGP of gynecologic tumors, with subsequent discus-
sion by an MTB, can provide results that can be implemented at the
point of care. Physicians can submit tumor tissue samples obtained in
the course of routine clinical care for genomic analysis with ease [50].
More speciﬁc identiﬁcation of tumors by genomic proﬁle, rather than
by tumor histologic subtype, may enable the physician to make more
informed decisions regarding therapeutic options and optimize the par-
ticipation inmolecularly appropriate clinical trials [50,51]. Furthermore,
despite the relatively high performance status of these patients at study
entry, manyMTB-based therapy recommendations could not be imple-
mented due to patients' deteriorating performance status, suggesting
that earlier initiation of genomically informed treatment decision-
making in patients with less advanced disease may result in improved
clinical impact. Patch et al. (2015) performed whole genome sequenc-
ing on individual patients with ovarian cancer and compared the results
to matched tumor samples from acquired drug resistant disease from
the same patients [22]. Interestingly, they found that high-grade serous
ovarian cancer could acquire resistance to ﬁrst-line, standard-of-care
therapy, and that new alterations in the resistant tumor were under se-
lection pressure [22]. Of signiﬁcance were the ﬁndings of multiple inde-
pendent reversions of germline BRCA1 and BRCA2 mutations, loss of
BRCA1 promoter methylation, and recurrent promoter fusion that re-
sulted in P-gp (ABCB1) overexpression. This provides a rationale for
conducting genomic proﬁling through CGP early in the tumor treatment
process (i.e., prior to initial therapy) so that targeted therapies could be
identiﬁed and utilized to potentially maximize outcomes before delete-
rious, cytotoxic drug resistance alterations populate the tumor. How-
ever, additional research is still needed to determine whether these
targeted therapies may contribute to further treatment resistance or
the development of new spectrum of genomic alterations. Our ap-
proach, while promising, has many challenges and needs to be inte-
grated into a setting of clinical trials and development of more
effective targeted drugs and multi-modality treatment.
Fig. 3.Progression-free survival on last therapy prior to and immediately following implementation ofMTB-based therapy. Day 0 represents thedate of initiation of anMTB-based therapy;
PFS = the duration (in days) from the initiation of an MTB-based therapy to patient progression or lack of clinical beneﬁt; purple bar= an MTB-based therapywas the same as the prior
therapy; two patients were excluded because they did not receive therapy. Arrows indicate ongoing PFS onMTB-based therapies. Data was last monitored for this paper on September 4,
2015. The designation of “ongoing” (represented by arrows) is based on the patient's last physician visit or the patient's status as of September 4, 2015.
8 L. Rodriguez-Rodriguez et al. / Gynecologic Oncology 141 (2016) 2–9Furthermore, in a subset of patients, reasons for delay of implemen-
tation of therapy could not be accurately measured. In most instances
insurance approvals and correspondence from the physician to the in-
surance carriers were required hence delaying beneﬁcial therapy to
some patients. All of the aspects of implementation need to be ad-
dressed further in order to improve on the time from treatment decision
to treatment delivery. Barriers to implementation of MTB-based thera-
peutic recommendationsmust be overcome in order to increase the po-
tential success of this treatment approach. For example, the
establishment of more genomically guided clinical trials at cancer cen-
ters would help increase the options available to patients. Speciﬁcally,
clinical trials with emphasis on speciﬁc molecular pathways or genomic
alterations, with lessweight given to tumor site or histology, could have
greater potential both for the clinical trial and the patient by tailoring
the speciﬁcations for maximum beneﬁt [51]. Lack of knowledge of
genomics and molecular pathways on the part of the treating oncol-
ogist may act as a barrier to the acceptance of MTB-based targeted
therapy recommendations as possible alternatives to standard-of-
care therapies. To overcome this barrier, oncologists of the future
should be well-versed in oncogenic pathways and molecular targets
of the new and available drugs. This can be accomplished through
MTBs, which work as educational tools through collective knowledge
and community growth.
There has been a recent surge in publications on proﬁling tumors
based on genomic markers, precision and targeted medicine, and the
development of MTBs [9,17,28,31,35,41–43,48,52–61], however, few
have addressed point-of-care feasibility given the longer times required
for CGP testing and interpretation. This current proof-of-concept study
shows that with a well-trained expert team, point-of-caremanagement
of gynecologic testing and management is feasible and patient beneﬁt
can be attained, supporting the need for further studies and guidelines
on clinical decisionmakingwith greater availability of broad genomically
based diagnostics.
Supplementary data to this article can be found online at http://dx.
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